Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7200220 intravitreal study in uveitic macular edema
NL-OMON59235Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vamikibart in noninfectious uveitis (NIU) and uveitic macular edema (UME) (2 arms), sponsored by Roche. Primary endpoint: Proportion of participants with at least 15-letter improvement from baseline in BCVA at Week 16. Started Jul 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
noninfectious uveitis (NIU)uveitic macular edema (UME)
Beyond the preview
Go deeper on NL-OMON59235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59235.